MEGAN NYEE MACKI: Open Payments
NPI 1417578584 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$415 in 22 payments from 10 companies in 2025. Trend: 2023 $314 · 2024 $540 · 2025 $415
Food & beverage: $415
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 6 | $105 |
| ABBVIE INC. | 4 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $52 |
| Astellas Pharma US Inc | 2 | $49 |
| Novo Nordisk Inc | 2 | $36 |
| AstraZeneca Pharmaceuticals LP | 2 | $30 |
| Lundbeck LLC | 1 | $20 |
| PFIZER INC. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Corium, LLC | 1 | $18 |
Products named: MOUNJARO, CAPLYTA, Veozah, VRAYLAR, REXULTI, PAXLOVID, GVOKE HYPOPEN, Azstarys.
Industry payments across IN — which companies pay providers there.
